Clinical research company IQVIA (NYSE: IQV) reported in Q3 CY2025, with sales up 5.2% year on year to $4.1 billion. The ...

IQVIA Holdings on Tuesday narrowed its annual profit forecast, trimming the upper end of its outlook, as it expects cancellations of research contracts from pharmaceutical clients to persist into the ...

DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA™ (NYSE:IQV) today announced the launch of the Patient Centered Endpoints (PCE) solution, an innovative science and ...

Clinical research company IQVIA (NYSE: IQV) reported Q3 CY2025 results topping the market’s revenue expectations, with sales ...

IQVIA Holdings has seen its consensus analyst price target rise slightly to $223 from $218, reflecting a modest uptick in ...

Iqvia's third-quarter net income and revenue rose amid growing demand for its healthcare technology and research services.

While the newly renamed IQVIA (NYSE: IQV) has been busy rolling out the first offering of its integration-focused technology for the commercial side of the pharmaceutical industry, offerings for the ...

IQVIA reaffirmed its full-year 2025 guidance, narrowing the ranges to revenue between $16.15 billion and $16.25 billion and adjusted earnings per share between $11.85 and $11.95, in line with analyst ...

Get key takeaways from IQVIA’s record Q3 2025—strong bookings, free cash flow, AI momentum, and guidance reaffirmed.

New multiyear collaboration between Florence Healthcare and IQVIA to ensure research sites participating in IQVIA studies have access to best-in-class site enablement technology to streamline ...

Gross Leverage Ratio (Gross Debt/LTM Adjusted EBITDA) 4.9x Net Leverage Ratio (Net Debt/LTM Adjusted EBITDA) 4.5x ...